Bicycle signs 15-year uranium contract with UK Nuclear Decommissioning Authority

Bicycle Therapeutics (BCYC) announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority for access to up to 400 tons of reprocessed uranium. RepU continually regenerates providing a potentially sustainable supply of 212Pb. Bicycle intends to utilize the RepU provided by this agreement in its development of potential lifesaving therapies. In addition, Bicycle announced a collaboration with United Kingdom National Nuclear Laboratory, pursuant to which it plans to extract 228Th from the RepU obtained from NDA. The extracted 228Th will then be further processed into 224Ra and loaded into a bespoke 212Pb generator being developed exclusively for Bicycle by SpectronRx. 212Pb is a radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha Therapy. Collectively, this bespoke set of arrangements is designed to support the potential discovery, development, and commercial supply of a portfolio of Bicycle Radioconjugates containing 212Pb.